Wesley Nuffer, Briana Williams, Jennifer M Trujillo. Ther Adv Endocrinol Metab 2019
Times Cited: 3
Times Cited: 3
Times Cited
Times Co-cited
Similarity
An introduction to drug disposition: the basic principles of absorption, distribution, metabolism, and excretion.
J Caldwell, I Gardner, N Swales. Toxicol Pathol 1995
J Caldwell, I Gardner, N Swales. Toxicol Pathol 1995
33
A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors.
Emily Brown, Surya P Rajeev, Daniel J Cuthbertson, John P H Wilding. Diabetes Obes Metab 2019
Emily Brown, Surya P Rajeev, Daniel J Cuthbertson, John P H Wilding. Diabetes Obes Metab 2019
33
Empagliflozin: a review of its use in patients with type 2 diabetes mellitus.
Lesley J Scott. Drugs 2014
Lesley J Scott. Drugs 2014
33
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Karen Whalen, Shannon Miller, Erin St Onge. Clin Ther 2015
Karen Whalen, Shannon Miller, Erin St Onge. Clin Ther 2015
33
Two Decades under the Influence of the Rule of Five and the Changing Properties of Approved Oral Drugs.
Michael D Shultz. J Med Chem 2019
Michael D Shultz. J Med Chem 2019
33
The use of radiolabeled compounds for ADME studies in discovery and exploratory development.
P H Marathe, W C Shyu, W G Humphreys. Curr Pharm Des 2004
P H Marathe, W C Shyu, W G Humphreys. Curr Pharm Des 2004
33
Canagliflozin review - safety and efficacy profile in patients with T2DM.
Haroon Jakher, Tara I Chang, Marilyn Tan, Kenneth W Mahaffey. Diabetes Metab Syndr Obes 2019
Haroon Jakher, Tara I Chang, Marilyn Tan, Kenneth W Mahaffey. Diabetes Metab Syndr Obes 2019
33
Syntheses of isotope-labeled SGLT2 inhibitor canagliflozin (JNJ-28431754).
Ronghui Lin, David C Hoerr, Larry E Weaner, Rhys Salter. J Labelled Comp Radiopharm 2017
Ronghui Lin, David C Hoerr, Larry E Weaner, Rhys Salter. J Labelled Comp Radiopharm 2017
100
What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs.
Sarah J Roffey, R Scott Obach, Jenny I Gedge, Dennis A Smith. Drug Metab Rev 2007
Sarah J Roffey, R Scott Obach, Jenny I Gedge, Dennis A Smith. Drug Metab Rev 2007
33
Recent advances in the applications of radioisotopes in drug metabolism, toxicology and pharmacokinetics.
D Dalvie. Curr Pharm Des 2000
D Dalvie. Curr Pharm Des 2000
33
An exhaustive perspective on structural insights of SGLT2 inhibitors: A novel class of antidiabetic agent.
Sushanta Bhattacharya, Akash Rathore, Deepa Parwani, Chaitali Mallick, Vivek Asati, Shivangi Agarwal, Vaibhav Rajoriya, Ratnesh Das, Sushil Kumar Kashaw. Eur J Med Chem 2020
Sushanta Bhattacharya, Akash Rathore, Deepa Parwani, Chaitali Mallick, Vivek Asati, Shivangi Agarwal, Vaibhav Rajoriya, Ratnesh Das, Sushil Kumar Kashaw. Eur J Med Chem 2020
100
Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis.
Nisa M Maruthur, Eva Tseng, Susan Hutfless, Lisa M Wilson, Catalina Suarez-Cuervo, Zackary Berger, Yue Chu, Emmanuel Iyoha, Jodi B Segal, Shari Bolen. Ann Intern Med 2016
Nisa M Maruthur, Eva Tseng, Susan Hutfless, Lisa M Wilson, Catalina Suarez-Cuervo, Zackary Berger, Yue Chu, Emmanuel Iyoha, Jodi B Segal, Shari Bolen. Ann Intern Med 2016
33
Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.
Ronnie Aronson, Juan Frias, Allison Goldman, Amanda Darekar, Brett Lauring, Steven G Terra. Diabetes Obes Metab 2018
Ronnie Aronson, Juan Frias, Allison Goldman, Amanda Darekar, Brett Lauring, Steven G Terra. Diabetes Obes Metab 2018
33
Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.
Atsunori Kashiwagi, Satoshi Yoshida, Ichiro Nakamura, Kenichi Kazuta, Eiji Ueyama, Hideyuki Takahashi, Hayato Satomi, Yoshinori Kosakai, Kosei Kawamuki. J Diabetes Investig 2016
Atsunori Kashiwagi, Satoshi Yoshida, Ichiro Nakamura, Kenichi Kazuta, Eiji Ueyama, Hideyuki Takahashi, Hayato Satomi, Yoshinori Kosakai, Kosei Kawamuki. J Diabetes Investig 2016
33
Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone.
Steven G Terra, Kristen Focht, Melanie Davies, Juan Frias, Giuseppe Derosa, Amanda Darekar, Gregory Golm, Jeremy Johnson, Didier Saur, Brett Lauring,[...]. Diabetes Obes Metab 2017
Steven G Terra, Kristen Focht, Melanie Davies, Juan Frias, Giuseppe Derosa, Amanda Darekar, Gregory Golm, Jeremy Johnson, Didier Saur, Brett Lauring,[...]. Diabetes Obes Metab 2017
33
Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Diab Vasc Dis Res 2015
Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Diab Vasc Dis Res 2015
33
Overweight and obesity as determinants of cardiovascular risk: the Framingham experience.
Peter W F Wilson, Ralph B D'Agostino, Lisa Sullivan, Helen Parise, William B Kannel. Arch Intern Med 2002
Peter W F Wilson, Ralph B D'Agostino, Lisa Sullivan, Helen Parise, William B Kannel. Arch Intern Med 2002
33
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
33
SGLT inhibitors in management of diabetes.
Abd A Tahrani, Anthony H Barnett, Clifford J Bailey. Lancet Diabetes Endocrinol 2013
Abd A Tahrani, Anthony H Barnett, Clifford J Bailey. Lancet Diabetes Endocrinol 2013
33
Efficacy and safety of luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus.
Yutaka Seino, Nobuya Inagaki, Masakazu Haneda, Kohei Kaku, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa. J Diabetes Investig 2015
Yutaka Seino, Nobuya Inagaki, Masakazu Haneda, Kohei Kaku, Takashi Sasaki, Atsushi Fukatsu, Michito Ubukata, Soichi Sakai, Yoshishige Samukawa. J Diabetes Investig 2015
33
Combination SGLT2 inhibitor and GLP-1 receptor agonist therapy: a complementary approach to the treatment of type 2 diabetes.
Robert S Busch, Michael P Kane. Postgrad Med 2017
Robert S Busch, Michael P Kane. Postgrad Med 2017
33
Thiazolylmethyl ortho-substituted phenyl glucoside library as novel C-aryl glucoside SGLT2 inhibitors.
Suk Ho Lee, Min Ju Kim, Sung-Han Lee, Jeongmin Kim, Hyun-Ju Park, Jinhwa Lee. Eur J Med Chem 2011
Suk Ho Lee, Min Ju Kim, Sung-Han Lee, Jeongmin Kim, Hyun-Ju Park, Jinhwa Lee. Eur J Med Chem 2011
33
Where does combination therapy with an SGLT2 inhibitor plus a DPP-4 inhibitor fit in the management of type 2 diabetes?
Muhammad Abdul-Ghani. Diabetes Care 2015
Muhammad Abdul-Ghani. Diabetes Care 2015
33
Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.
Abdullah Kaplan, Emna Abidi, Ahmed El-Yazbi, Ali Eid, George W Booz, Fouad A Zouein. Heart Fail Rev 2018
Abdullah Kaplan, Emna Abidi, Ahmed El-Yazbi, Ali Eid, George W Booz, Fouad A Zouein. Heart Fail Rev 2018
33
Sugar-sweetened beverages, obesity, type 2 diabetes mellitus, and cardiovascular disease risk.
Vasanti S Malik, Barry M Popkin, George A Bray, Jean-Pierre Després, Frank B Hu. Circulation 2010
Vasanti S Malik, Barry M Popkin, George A Bray, Jean-Pierre Després, Frank B Hu. Circulation 2010
33
Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Yoshihito Ohtake, Tsutomu Sato, Takamitsu Kobayashi, Masahiro Nishimoto, Naoki Taka, Koji Takano, Keisuke Yamamoto, Masayuki Ohmori, Marina Yamaguchi, Kyoko Takami,[...]. J Med Chem 2012
Yoshihito Ohtake, Tsutomu Sato, Takamitsu Kobayashi, Masahiro Nishimoto, Naoki Taka, Koji Takano, Keisuke Yamamoto, Masayuki Ohmori, Marina Yamaguchi, Kyoko Takami,[...]. J Med Chem 2012
33
Synthesis and biological evaluation of 6-hydroxyl C-aryl glucoside derivatives as novel sodium glucose co-transporter 2 (SGLT2) inhibitors.
Xiaoyu Zhao, Bin Sun, Hongbo Zheng, Jun Liu, Lilin Qian, Xiaoning Wang, Hongxiang Lou. Bioorg Med Chem Lett 2018
Xiaoyu Zhao, Bin Sun, Hongbo Zheng, Jun Liu, Lilin Qian, Xiaoning Wang, Hongxiang Lou. Bioorg Med Chem Lett 2018
33
Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study.
Ichiro Nakamura, Hiroshi Maegawa, Kazuyuki Tobe, Hiromi Tabuchi, Satoshi Uno. Expert Opin Pharmacother 2018
Ichiro Nakamura, Hiroshi Maegawa, Kazuyuki Tobe, Hiromi Tabuchi, Satoshi Uno. Expert Opin Pharmacother 2018
33
C-Aryl glucoside SGLT2 inhibitors containing a biphenyl motif as potential anti-diabetic agents.
Yuyang Ding, Liufeng Mao, Dengfeng Xu, Hui Xie, Ling Yang, Hongjiang Xu, Wenjun Geng, Yong Gao, Chunguang Xia, Xiquan Zhang,[...]. Bioorg Med Chem Lett 2015
Yuyang Ding, Liufeng Mao, Dengfeng Xu, Hui Xie, Ling Yang, Hongjiang Xu, Wenjun Geng, Yong Gao, Chunguang Xia, Xiquan Zhang,[...]. Bioorg Med Chem Lett 2015
33
Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review.
Subham Das, Anu K R, Sumit Raosaheb Birangal, Ajinkya Nitin Nikam, Abhijeet Pandey, Srinivas Mutalik, Alex Joseph. Life Sci 2020
Subham Das, Anu K R, Sumit Raosaheb Birangal, Ajinkya Nitin Nikam, Abhijeet Pandey, Srinivas Mutalik, Alex Joseph. Life Sci 2020
33
Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors.
Junwon Lee, Jong Yup Kim, Jungsub Choi, Sung-Han Lee, Jeongmin Kim, Jinhwa Lee. Bioorg Med Chem Lett 2010
Junwon Lee, Jong Yup Kim, Jungsub Choi, Sung-Han Lee, Jeongmin Kim, Jinhwa Lee. Bioorg Med Chem Lett 2010
33
Concise and Stereodivergent Synthesis of Carbasugars Reveals Unexpected Structure-Activity Relationship (SAR) of SGLT2 Inhibition.
Wai-Lung Ng, Ho-Chuen Li, Kit-Man Lau, Anthony K N Chan, Clara Bik-San Lau, Tony K M Shing. Sci Rep 2017
Wai-Lung Ng, Ho-Chuen Li, Kit-Man Lau, Anthony K N Chan, Clara Bik-San Lau, Tony K M Shing. Sci Rep 2017
50
Long-term safety and efficacy of tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, as monotherapy or in combination with other oral antidiabetic agents in Japanese patients with type 2 diabetes mellitus: multicenter, open-label, randomized controlled trials.
Yukio Tanizawa, Kohei Kaku, Eiichi Araki, Kazuyuki Tobe, Yasuo Terauchi, Kazunori Utsunomiya, Yasuhiko Iwamoto, Hirotaka Watada, Wataru Ohtsuka, Daisuke Watanabe,[...]. Expert Opin Pharmacother 2014
Yukio Tanizawa, Kohei Kaku, Eiichi Araki, Kazuyuki Tobe, Yasuo Terauchi, Kazunori Utsunomiya, Yasuhiko Iwamoto, Hirotaka Watada, Wataru Ohtsuka, Daisuke Watanabe,[...]. Expert Opin Pharmacother 2014
33
LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.
B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh,[...]. Clin Pharmacol Ther 2012
B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh,[...]. Clin Pharmacol Ther 2012
33
Synthesis and biological evaluation of novel tetrahydroisoquinoline-C-aryl glucosides as SGLT2 inhibitors for the treatment of type 2 diabetes.
Xuan Pan, Yi Huan, Zhufang Shen, Zhanzhu Liu. Eur J Med Chem 2016
Xuan Pan, Yi Huan, Zhufang Shen, Zhanzhu Liu. Eur J Med Chem 2016
33
Modification on the O-glucoside of Sergliflozin-A: A new strategy for SGLT2 inhibitor design.
Xuefeng Cao, Wenpeng Zhang, Xu Yan, Zhi Huang, Zhenqing Zhang, Peng Wang, Jie Shen. Bioorg Med Chem Lett 2016
Xuefeng Cao, Wenpeng Zhang, Xu Yan, Zhi Huang, Zhenqing Zhang, Peng Wang, Jie Shen. Bioorg Med Chem Lett 2016
33
Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 Inhibitors.
Kwang-Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Junwon Lee, Sung-Han Lee, Myung Eun Jung, Eun-Jung Son, MinWoo Lee, Jeongmin Kim,[...]. ACS Med Chem Lett 2010
Kwang-Seop Song, Suk Ho Lee, Min Ju Kim, Hee Jeong Seo, Junwon Lee, Sung-Han Lee, Myung Eun Jung, Eun-Jung Son, MinWoo Lee, Jeongmin Kim,[...]. ACS Med Chem Lett 2010
33
33
Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study.
Priscilla Hollander, Jie Liu, Julie Hill, Jeremy Johnson, Zhi Wei Jiang, Gregory Golm, Susan Huyck, Steven G Terra, James P Mancuso, Samuel S Engel,[...]. Diabetes Ther 2018
Priscilla Hollander, Jie Liu, Julie Hill, Jeremy Johnson, Zhi Wei Jiang, Gregory Golm, Susan Huyck, Steven G Terra, James P Mancuso, Samuel S Engel,[...]. Diabetes Ther 2018
33
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial.
David Fitchett, Bernard Zinman, Christoph Wanner, John M Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. Eur Heart J 2016
David Fitchett, Bernard Zinman, Christoph Wanner, John M Lachin, Stefan Hantel, Afshin Salsali, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Silvio E Inzucchi. Eur Heart J 2016
33
The effect of dapagliflozin on renal function in patients with type 2 diabetes.
Donald Elliott Kohan, Paola Fioretto, Kristina Johnsson, Shamik Parikh, Agata Ptaszynska, Lisa Ying. J Nephrol 2016
Donald Elliott Kohan, Paola Fioretto, Kristina Johnsson, Shamik Parikh, Agata Ptaszynska, Lisa Ying. J Nephrol 2016
33
Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
Robert R Henry, Julio Rosenstock, Steven Edelman, Sunder Mudaliar, Alexandros-Georgios Chalamandaris, Sreeneeranj Kasichayanula, Allyson Bogle, Nayyar Iqbal, James List, Steven C Griffen. Diabetes Care 2015
33
Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, ameliorates the development of liver fibrosis in diabetic Otsuka Long-Evans Tokushima fatty rats.
Norihisa Nishimura, Mitsuteru Kitade, Ryuichi Noguchi, Tadashi Namisaki, Kei Moriya, Kosuke Takeda, Yasushi Okura, Yosuke Aihara, Akitoshi Douhara, Hideto Kawaratani,[...]. J Gastroenterol 2016
Norihisa Nishimura, Mitsuteru Kitade, Ryuichi Noguchi, Tadashi Namisaki, Kei Moriya, Kosuke Takeda, Yasushi Okura, Yosuke Aihara, Akitoshi Douhara, Hideto Kawaratani,[...]. J Gastroenterol 2016
33
Identification of a novel Na+/myo-inositol cotransporter.
Michael J Coady, Bernadette Wallendorff, Dominique G Gagnon, Jean-Yves Lapointe. J Biol Chem 2002
Michael J Coady, Bernadette Wallendorff, Dominique G Gagnon, Jean-Yves Lapointe. J Biol Chem 2002
33
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Lawrence A Leiter, Kun-Ho Yoon, Pablo Arias, Gisle Langslet, John Xie, Dainius A Balis, Dawn Millington, Frank Vercruysse, William Canovatchel, Gary Meininger. Diabetes Care 2015
Lawrence A Leiter, Kun-Ho Yoon, Pablo Arias, Gisle Langslet, John Xie, Dainius A Balis, Dawn Millington, Frank Vercruysse, William Canovatchel, Gary Meininger. Diabetes Care 2015
33
Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.
J P H Wilding, E Ferrannini, V A Fonseca, W Wilpshaar, P Dhanjal, A Houzer. Diabetes Obes Metab 2013
J P H Wilding, E Ferrannini, V A Fonseca, W Wilpshaar, P Dhanjal, A Houzer. Diabetes Obes Metab 2013
33
Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects.
Leo Seman, Sreeraj Macha, Gerhard Nehmiz, Gudrun Simons, Bailuo Ren, Sabine Pinnetti, Hans J Woerle, Klaus Dugi. Clin Pharmacol Drug Dev 2013
Leo Seman, Sreeraj Macha, Gerhard Nehmiz, Gudrun Simons, Bailuo Ren, Sabine Pinnetti, Hans J Woerle, Klaus Dugi. Clin Pharmacol Drug Dev 2013
33
The effect of moderate hepatic impairment on the pharmacokinetics of ipragliflozin, a novel sodium glucose co-transporter 2 (SGLT2) inhibitor.
Wenhui Zhang, Walter J J Krauwinkel, James Keirns, Robert W Townsend, Kenneth C Lasseter, Lisa Plumb, Takeshi Kadokura, Fumihiko Ushigome, Ronald Smulders. Clin Drug Investig 2013
Wenhui Zhang, Walter J J Krauwinkel, James Keirns, Robert W Townsend, Kenneth C Lasseter, Lisa Plumb, Takeshi Kadokura, Fumihiko Ushigome, Ronald Smulders. Clin Drug Investig 2013
33
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.